Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today provided the following statement after the conclusion of the
Peripheral and Central Nervous System Drugs Advisory Committee meeting
of the U.S. Food and Drug Administration (FDA) about suvorexant, Mercks
investigational medicine to treat insomnia.
Language:
English
Contact HTML:
MerckMedia:Pam Eisele, 908-423-5042orTracy Ogden, 267-305-2301orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more